PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Am Chem Soc. Author manuscript; available in PMC 2009 March 5.
Published in final edited form as:
PMCID: PMC2651819
NIHMSID: NIHMS94211

Lactimidomycin, Iso-migrastatin and Related Glutarimide-containing 12-membered Macrolides are Extremely Potent Inhibitors of Cell Migration

Abstract

Migrastatin (1), iso-migrastatin (5) and lactimidomycin (7) are all glutarimide-containing polyketides known for their unique structures and cytotoxic activities against human cancer cell lines. Migrastatin, a strong inhibitor of tumor cell migration, has been an important lead in the development of antimetastatic agents. Yet studies of the related 12-membered macrolides iso-migrastatin, lactimidomycin and related analogs have been hampered by their limited availability. We report here the production, isolation, structural characterization and biological activities of iso-migrastatin, lactimidomycin, and 23 related congeners. Our studies showed that, as a family, the glutarimide-containing 12-membered macrolides are extremely potent cell migration inhibitors with some members displaying activity on par or superior to that of migrastatin as exemplified by compounds 5, 7, and 912. On the basis of these findings, the structures and activity of this family of compounds as cell migration inhibitors are discussed.

Migrastatin (MGS, 1) is a glutarimide-containing 14-membered macrolide originally isolated from Streptomyces sp. MK929-43F1. It was later found in fermentation broths of S. platensis, and has been extensively studied for its ability to inhibit cell migration.14 Potentially useful antimetastasis activities of this glutarimide-containing polyketide and numerous truncated synthetic derivatives including 24 (Fig. 1) have been experimentally correlated to in vitro and in vivo cell migration inhibition.2,5,6 The MGS core 2 is the most potent cell migration inhibitor published to date with an IC50 of 22 nM.2

Figure 1
Structures of the natural products migrastatin (1), iso-migrastatin (5) and lactimidomycin (7), fully synthetic macrolactone (2), macroketone (3), macrolactam (4),2 and semi-synthetic 2, 3-dihydroiso-migrastatin (6), and 2, 3-dihydro-lactimidomycin ( ...

MGS is a shunt metabolite of the 12-membered macrolide-containing polyketide iso-migrastatin (iso-MGS, 5)4 that is known to undergo facile hydrolytic and thermolytic transformations yielding a wide array of ring expanded and ring-opened analogs.79 Like 5, lactimidomycin (LTM, 7) is a 12-membered unsaturated macrolide antibiotic characterized by a biosynthetically rare glutarimide sidechain.10 LTM, first discovered in 1992 from fermentations of Streptomyces amphibiosporus ATCC53964, displays strong in vitro cytotoxicity against a number of human cell lines (IC50 = 3.0 ~ 65 nM), in vivo antitumor activity in mice, potent antifungal activity, and inhibits both DNA and protein synthesis.10 Studies of 5 and 7 have been extremely limited, due principally to low fermentation titers. Although the total synthesis of 5 has recently been accomplished and will surely contribute to the development of new cell migration inhibitors, no total synthesis of LTM has yet appeared.11

We have optimized the fermentation of microorganisms leading to significant improvements in target natural product titers, the ability to recover previously undetected minor metabolites, and significantly more efficient, less costly, and greener secondary metabolite extractions. Exemplary in this regard has been our use of XAD-16 resin to extract 1, 5, and related metabolites 912, and 14 from S. platensis8 as well as 7 and 13 from S. amphibiosporus (Fig. 2).12 We now report the isolation, structural characterization and biological activity of 12-membered structural relatives of 14-membered lead compound 1 and semi-synthetic derivatives thereof (1729). Many of these 12-membered macrolides inhibited tumor cell migration with potencies far surpassing that of 1 and very much on par with the MGS core 2.

Figure 2
Structures of LTM and iso-MGS congeners subjected to SWH assays en route to evaluation as cell migration inhibitors.13a Compound 27 is the 8-(S)-epimer of compound 24.

The effects of 529 on the migration of 4T1 mouse mammary tumor and MDA-MB-231 cells were investigated using standardized scratch wound healing (SWH) assays and IC50s for cell migration inhibition compared to the structurally related and extensively studied 1.2,14 Compound cytotoxicities were also determined to establish clear independence of cell migration inhibition from the possible effects of cell death.14

An impressive 14 compounds (5, 712, 14, 17, 20, 23, and 2527) out of the collection tested inhibit tumor cell migration more potently than 1 suggesting the general superiority of the 12-membered glutarimide-capped macrolides relative to their 14-membered MGS cousins (Table 1).14 Particularly striking are 5 and 7; both inhibited cell migration with potencies in the low nM range, approximately three orders of magnitude better than 1 and superior in some cases to the synthetic MGS analog 2. Of the compounds evaluated 13, 15, 16, and 24 were found to be too toxic for SWH assays; these are therefore not included in Table 1.

Table 1
Summary IC50 values of cell migration inhibitiona and cytotoxicity for 12-membered macrolides 529 in comparison with the 14-membered 1.b

The wide variance of activity among 529 gives insight into how structural features attenuate activity. Because 529 all retain the 12-membered macrolide, changes in activity can be correlated to one or a combination of alterations to three key functionalities including; (i) the glutarimide sidechain, (ii) oxidation state of the C2-C3 bond, and (iii) alteration of C8 and C9 substitution patterns.

We have found with MGS congeners that hydroxylation at C17 profoundly improves activity relative to the fully saturated and 16, 17-didehydro analogs.14 Activity improvement by C17 hydroxylation is apparent also across 529. Comparison of IC50 values for wound healing inhibition by 6 and 17 to inhibition by 20, as well as wound healing inhibition by 18 and 19 to inhibition by 25 substantiates the influence of C17 hydroxylation. The latter case is particularly dramatic as both 18 and 19 are devoid of activity while 25 possesses an IC50 of ~260 nM. Iso-MGS, lacking the C17 hydroxyl moiety, displays cell migration inhibitory activity far greater than its hydroxylated counterpart 12 although multiple modes of target binding may account for this exception to the rule.14

Isolation of 5, 7, 912, 1416 permitted semi-synthetic production of 2, 3-dihydro analogs 6, 8, 1727 (Supporting Information) and cysteine conjugates 28 and 29.8 In tandem with SWH assays, the importance of the C2, C3-olefin is made clear; reduction adducts 6 and 8 display IC50s at least 100-fold higher than observed for their unsaturated precursors 5 and 7, respectively. Comparison of IC50 values for the olefinic compounds 911, and 14 to their reduced analogs 1719, and 22 respectively, also reveals a pronounced reduction in the ability of reduced congeners to inhibit cell migration. Particularly striking is that reduction of compound 14 (IC50 = 3.9 nM) affords 22, a compound completely devoid of activity. Among the glutarimide containing 12-membered macrolides, the C2, C3-olefin plays a vital role. Possibly important to understanding how best to optimize the pharmacokinetics of such compounds, this assertion is further supported by the inability of cysteine conjugates 28 and 29 derived from 5 and 14, respectively, to inhibit tumor cell migration.

The results of SWH assays reveal that, all other factors being equal, the extent of macrolide oxygenation alters activity although not to the extent of C17 oxidation or enone reduction. As reflected by comparing the activity of compounds 9 to 11; 10 to 5 and 14; and 20 to 23, 25, and 27, it is evident that increased macrolide polarity via C8 and/or C9 oxygenation results in moderately improved activity. Comparison of the activities of 23 to 27 suggests that macrolide OH moieties may serve as vital H-bond donors. This is in contrast to previous studies in which increased polarity of 14-membered macrolide congeners of 1 led to reduced activity in SWH assays.14

Finally, cytotoxic IC50s for the majority of new compounds were determined to be well above those found for cell migration inhibition, a property that is highly desirable for antimetastatic agents where cell killing is not the intended goal.14

These studies highlight structural features critical to the potential of glutarimide-containing polyketides as antimetastasis agents. However, the most striking feature of this work is the dramatic potency of 5 and 7 revealed by SWH assays. These, and related compounds such as 912 will serve as excellent leads to advance the development of this family of natural products and their analogs as antimetastasis agents for the control and eradication of human cancers.

Acknowledgments

We thank the Analytical Instrumentation Center of the School of Pharmacy, UW-Madison for support in obtaining MS and NMR data. This work is supported in part by NIH grants CA106150 and CA113297.

Footnotes

Supporting Information Available: Full experimental details, 1H and 13C NMR data and assignments for compounds 6, 8, and 1727 are available free of charge via the Internet at http://pubs.acs.org.

References & Notes

1. Perez L, Danishefsky SJ. ACS Chem Biol. 2007;2:159–162. [PubMed]
2. Gaul C, Njardarson JT, Shan D, Dorn DC, Wu D-D, Tong WP, Huang X-Y, Moore MAS, Danishefsky SJ. J Am Chem Soc. 2004;126:11326–11337. [PubMed]
3. Nakae K, Yoshimoto Y, Sawa T, Homma Y, Hamada M, Takeuchi T, Imoto M. J Antibiot. 2000;53:1130–1136. [PubMed]
4. Woo EJ, Starks CM, Carney JR, Arslanian R, Cadapan L, Zavala S, Licari P. J Antibiot. 2002;55:141–146. [PubMed]
5. Njardarson JT, Gaul C, Shan D, Huang X-Y, Danishefsky SJ. J Am Chem Soc. 2004;126:1038–1039. [PubMed]
6. Shan D, Chen L, Njardarson JT, Gaul C, Ma X, Danishefsky SJ. Proc Natl Acad Sci USA. 2005;102:3772–3776. [PubMed]
7. Ju J, Lim S-K, Jiang H, Shen B. J Am Chem Soc. 2005;127:1622–1623. [PubMed]
8. Ju J, Lim S-K, Jiang H, Seo J-W, Shen B. J Am Chem Soc. 2005;127:11930–11931. [PubMed]
9. Ju J, Lim S-K, Jiang H, Seo J-W, Her Y, Shen B. Org Lett. 2006;8:5865–5868. [PMC free article] [PubMed]
10. Sugawara K, Nishiyama Y, Toda S, Komiyama N, Hatori M, Moriyama T, Sawada Y, Kamei H, Konishi M, Oki T. J Antibiot. 1992;45:1433–1441. [PubMed]
11. Krauss IJ, Mandal M, Danishefsky SJ. Angew Chem Int Ed. 2007;46:5576–5579. [PubMed]
12. Ju J, Seo J-W, Her Y, Lim S-K, Shen B. Org Lett. 2007;9:5183–5186. [PubMed]
13. Compounds 9–14 were isolated from S. platensis and S. amphibiosporus and have been previously reported7,12 as have 28 and 29.8 Compounds 15 and 16 were isolated from recombinant S. amphibiosporus and 17–27 were derived semi-synthetically (see Supporting Information).
14. For related studies of 1 and congeners see: Ju J, Rajski SR, Lim S-K, Seo J-W, Peters NR, Hoffmann FM, Shen B Bioorg Med Chem Lett. doi: 10.1016/j.bmcl.2008.07.072. [PMC free article] [PubMed] [Cross Ref]